---
title: GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy
  in early breast cancer
date: '2024-07-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39080281/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240731181850&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: GAIN-2 trial evaluated the optimal intense dose-dense (idd) strategy
  for high-risk early breast cancer. This study reports the secondary endpoints pathological
  complete response (pCR) and overall survival (OS). Patients (n = 2887) were randomized
  1:1 between idd epirubicin, nab-paclitaxel, and cyclophosphamide (iddEnPC) versus
  leukocyte nadir-based tailored regimen of dose-dense EC and docetaxel (dtEC-dtD)
  as adjuvant therapy, with neoadjuvant therapy allowed after amendment. At median
  ...
disable_comments: true
---
GAIN-2 trial evaluated the optimal intense dose-dense (idd) strategy for high-risk early breast cancer. This study reports the secondary endpoints pathological complete response (pCR) and overall survival (OS). Patients (n = 2887) were randomized 1:1 between idd epirubicin, nab-paclitaxel, and cyclophosphamide (iddEnPC) versus leukocyte nadir-based tailored regimen of dose-dense EC and docetaxel (dtEC-dtD) as adjuvant therapy, with neoadjuvant therapy allowed after amendment. At median ...